Biocept Continues International Expansion through Agreement with Quest Diagnostics Mexico
Biocept's Liquid Biopsy Test that Detects EGFR Mutations Associated with Lung Cancer to be Easily Accessible in Mexico
SAN DIEGO, April 18, 2016 -- Biocept, Inc. (NASDAQ: BIOC) continues to expand internationally by announcing that its Target Selector™ industry-leading blood-based test to detect EGFR mutations associated with lung cancer will now be accessible to patients in Mexico through a reference agreement with Quest Diagnostics Mexico. Terms of the transaction were not disclosed. Biocept is a leading molecular diagnostics company that commercializes and develops liquid biopsy tests for cancer profiling and monitoring.
- Published: 18 April 2016
- Written by Editor